Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period

• Main Authors: Hyuk Huh (Author), Yong Soo Kim (Author), Wookyung Chung (Author), Yong Lim Kim (Author), Yaerim Kim (Author), Seungyeup Han (Author), Yeonsoon Jung (Author), Ki Young Na (Author), Kyu Beck Lee (Author), Yun Kyu Oh (Author), Hyeong Cheon Park (Author), Seung Hyeok Han (Author), Tae Hyun Yoo (Author), Yeong Hoon Kim (Author), Soo Wan Kim (Author), Kang Wook Lee (Author), Hayne Cho Park (Author), Sung Gyun Kim (Author), Hyunsuk Kim (Author), Chang Hwa Lee (Author), Kyongtae T. Bae (Author), Kook Hwan Oh (Author), Curie Ahn (Author), Hyun Jin Ryu (Author), Yong Chul Kim (Author)
• Format: Book
• Published: The Korean Society of Nephrology, 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background Tolvaptan reduces height-adjusted total kidney volume (htTKV) and renal function decline in autosomal dominant polycystic kidney disease (ADPKD). This study was aimed at investigating the efficacy and safety of tolvaptan in Korean patients with ADPKD during the titration period. Methods T...